---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-068011"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:11:09.629398+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer

## Summary
- Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.
- Cruse granted option for 25,000 shares vesting in 48 equal monthly installments; severance extended to 12 months post-change-of-control.
- Jennifer P. Lam named principal financial and accounting officer effective March 31, 2022; base salary raised to $320K (from $309K).
- Lam granted option for 10,000 shares vesting over 48 months; she previously served as VP of Finance & Administration since August 2021.

## SEC filing metadata
- accession: 0001193125-22-068011
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/d326180d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-068011
- JSON: https://secwatch.observer/filing/0001193125-22-068011.json
- Plain text: https://secwatch.observer/filing/0001193125-22-068011.txt

## Key facts
- Executive change
  Jennifer P. Lam was appointed as principal financial and accounting officer at OnKure Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial and accounting officer
  source text: On March 2, 2022, the Board appointed Jennifer P. Lam, the Company’s Vice President of Finance & Administration, as the Company’s principal financial and accounting officer, effective March 31, 2022 (the “Lam Appointment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm
- Executive change
  Michael P. Cruse was appointed as Chief Operating Officer at OnKure Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On March 2, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”) appointed Michael P. Cruse as the Company’s Chief Operating Officer, effective immediately (the “Cruse Appointment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.